Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective intra-arterial nivolumab via superficial temporal artery for recurrent/metastatic head and neck cancer
jRCTs041220157Completed
- Sponsor
- Central Japan International Medical Center
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in head and neck cancer (HNC), sponsored by Central Japan International Medical Center. Primary endpoint: Safety of nivolumab intra-arterial infusion. Started Mar 2023; status: completed.
02
Drugs
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on jRCTs041220157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220157.